were assessed at 4,12 and 24 weeks after injection. Treatment consisted of 30 injections distribuited into the detrusor muscle, avoiding trigone. The primary outcome was change in clinical status, including urinary frequency, urgency and urinary urgency incontinence (UUI) episodes. Secondary outcomes were changes in maximum cystometric capacity (MCC), volume at first desire to void (FDV) and post-void residual (PVR). Quality of life (QoL) was assessed using a visual analogue scale (VAS,0-10) and a patient global impression of improvement (PGI-I).Urinary retention, urinary tract infection (UTI) and required clean intermitent catheterization (CIC) were adverse events.
INTRODUCTION AND OBJECTIVES: Micro RNAs (miRs) are non-coding strands of RNA involved in gene expression. Because of their relative stability in urine and serum, miRs are widely researched as promising biomarkers that may better help understand chronic diseases. The role of miRs in the pathology and treatment outcomes of onabotulinumtoxin-A (onaBoNT-A) in overactive bladder (OAB) patients is unknown. Here, we identified the miRs associated with elevated postvoid residual volumes (PVRs) >200ml following intradetrusor injection of onaBoNT-A 100IU.
METHODS: 14 female OAB patients with urgency urinary incontinence refractory to OAB drugs were consented for this study. Cystoscopic-guided punch bladder biopsy was obtained at the time of injecting 100 units of onaBoNT-A. RNA was extracted from the biopsy for measuring the expression of 13 miR species using TaqMan Universal PCR Master Mix in quantitative PCR. The miR species were selected for their known effect on neurotrophin expression and smooth muscle function. Relative expression for each miR was determined after normalizing to U6 small nuclear RNA. PVRs and urine Nerve Growth Factor (NGF) levels were measured at baseline and at the follow-up visit 3 weeks later.
RESULTS: Consented 14 patients had a mean age of 66 years (Range 46-80 years). Of these patients, 9 maintained PVRs < 200mL (0-120 mL) after injection of onaBoNT-A to comprise the low PVR group. The other 5 patients developed , and they comprise the high PVR group. The mean pre-procedure PVR was similar in both groups. Relative expression of miR221 and miR125b (see Figure 1 ) was upregulated by 11 and 2 fold, respectively (*p<0.05, Mann-Whitney U test) in patients who maintained low PVRs after onaBoNT-A. The expression of other 11 miR species and urine NGF levels at baseline were not significantly different between the two groups. Even though the NGF levels were similar in two groups but the 11 fold downregulation of miR221 may attenuate the action of NGF in high PVR group.
CONCLUSIONS: This study suggests that deficiency in the pretreatment expression of miR221 and miR125b may predispose OAB patients to high PVRs following intradetrusor onaBoNT-A. Additional studies are needed to understand the role of each miR in OAB pathology and treatment outcomes. is an effective treatment for idiopathic detrusor overactivity of which urinary tract infections (UTIs) are a common complication. We previously identified a UTI rate of 35.1% in patients who received a single intramuscular (IM) dose of a third-generation cephalosporin (ceftriaxone) at the time of Botox injection. Given this high rate of infection despite single-dose antibiotic prophylaxis, we changed our practice pattern to determine if a longer course of antibiotic treatment would decrease the UTI rate following intravesical Botox injection.
METHODS: We retrospectively evaluated patients undergoing intravesical Botox injections from May 2012 to November 2016. All procedures were performed at the same office location. One group of patients, with negative pre-procedure urine cultures, was given an IM dose of a third-generation cephalosporin. A second group, also with negative pre-procedure cultures, received a 3-day course of an oral fluoroquinolone starting the day before Botox injection. Data abstracted included age, BMI, history of diabetes, pre/post procedure urine culture. Pre-procedure UTI was defined as asymptomatic bacteriuria. The postprocedure UTI rate was examined using a c 2 test. A secondary analysis was performed using logistic regression modeling to test the association between clinical characteristics and antibiotic regimen and risk of postprocedure UTI.
RESULTS: 284 Botox injections were performed over the study period -236 patients received a single IM dose of ceftriaxone and 48 patients received three days of oral ciprofloxacin. There was no difference in the baseline age, BMI, diabetes, or rate of pre-procedure positive culture between the two groups. Overall, the UTI rate was significantly lower in the fluoroquinolone group (20.8%) vs. the e1048 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 cephalosporin group (36%), p¼0.042. On multivariable regression analysis, predictors of post-procedure UTI included single IM dose of prophylaxis (OR 2.80, 95% CI 1.2-6.5, p¼0.016) and positive preprocedure urine culture (OR 1.31, 95% CI 1.03-1.66, p¼0.027). Age, BMI and diabetes were not associated with post-procedure UTI. CONCLUSIONS: In our series comparing two different antibiotic prophylaxis regimens for Botox injection, we found a significantly lower rate of UTI when patients received a three-day course of an oral fluoroquinolone as opposed to a single IM dose of a third-generation cephalosporin. Patients with a positive pre-procedure culture may benefit from longer duration of antibiotics at the time of Botox injection. 
Source of

INTRODUCTION AND OBJECTIVES:
The etiology of urinary incontinence is unknown. Beside stress urinary incontinence (SUI), current treatment options are based on a neurological disorder or the detrusor. In the early 90s Ulmsten and DeLancey hypothesized an anatomical defect of the anterior vaginal wall: laxity of the 3 levels (the paraurethral tissue, the apical end and vesicourethral junction). Except SUI, and in regard to materials (length/width) and fixation/implantation sides no standardized surgical treatment for these levels were developed. We introduced a standardized apical fixation: a bilateral mesh augmentation of the uterosacral ligaments: the cervicosacropexy (CESA) or vaginosacropexy (VASA). In order to evaluate the different hypotheses we compared the standard pharmacological treatment with the surgical approach of CESA or VASA in the treatment of urgency urinary incontinence (UUI) in women. Comparison of therapeutic efficacy between solifenacin and CESA or VASA surgeries in women with involuntary urinary leakage.
METHODS: Women with UUI symptoms and without previous treatment were eligible for this study. The study was approved by the local ethical committee (ClinicalTrails.gov Identifier: NCT01737411). UUI symptoms were assessed according to validated questionnaires. Urodynamics were performed before and after each treatment arm. Patients were randomized either in the solifenacin therapy arm (10mg) or in the surgical procedure arm. After 4 months the efficacy of each treatment arm was assessed. Cure was defined as voiding frequency <8 times/day and no involuntary leakage of urine. Polyvinylidene fluoride (PVDF) tapes of identical length were used for open abdominal USL augmentation and named cervicosacropexy (CESA) or vaginosacropexy (VASA) depending on the site of fixation. These tapes were sutured either on the cervix or vaginal stump and placed under the left and right peritoneal fold of the USL from the rectum and attached to the prevertebral fascia of the S1/S2 sacral vertebra.
RESULTS: 77 patients were evaluable for analysis. In total, after primary and secondary solifenacin treatment 3 out of 58 patients (5%) were cured. After primary and secondary CESA or VASA surgical treatment 26 out of 65 patients (40%) were cured of their UUI symptoms.
CONCLUSIONS: The CESA and VASA surgical procedures provide a therapy to cure 40% of patients from involuntary urinary leakage. Compared to the standard pharmacological treatment these surgical procedure depicts an option in the treatment of UUI. PD54-10   THE VALUE OF COMBINING LOW DOSE TROSPIUM  CHLORIDE WITH TRANSCUTANEOUS POSTERIOR TIBIAL  NERVE STIMULATION IN THE TREATMENT OF  OVERACTIVE BLADDER IN FEMALES Amr Abulseoud*, Gaber Ali, Mohamed Hassouna, Ahmed Moussa, Ibrahim Ibrahim, Emmanuel Saba, Alexandria, Egypt INTRODUCTION AND OBJECTIVES: This study was done to verify whether the combination of transcutaneous posterior tibial nerve stimulation (TPTNS) with low dose trospium chloride in the treatment of females with overactive bladder (OAB) would be more effective than TPTNS alone after failure of behavioral therapy.
Source of Funding: None
METHODS: We randomized 30 women with OAB, in two groups: G I (15 patients) received 30 minutes TPTNS, three times a week; GII (15 patients) received TPTNS plus Low dose trospium chloride (20 mg once daily); all for 8 weeks. Patients were evaluated using Overactive Bladder Symptom Score questionnaire (OABSS) which includes 3 categories (score < 5 ¼ mild symptoms, 6-11 ¼ moderate symptoms, > 12 ¼ severe symptoms), Incontinence Impact Questionnaire-short form 7 (IIQ-7) which includes 3 categories (score < 50% ¼ good quality of life, 50-70% ¼ moderate quality of life and > 70 ¼ poor quality of life), 3 day voiding diary and urodynamics at weeks 0 and 8. RESULTS: The groups were similar before treatment. After treatment both groups improved regarding all the parameters, however group II showed more significant improvement. The OABSS was reduced from 13.0 AE 1.31 to 8.53 AE 1.30 (p<0.001) and from 12.67 AE 1.95 to 10.0 AE 2.0 (p<0.001) in GII and GI respectively. Improvement (change from one category to a better one) occurred in 8 (53.3%) and in 14 (93.3%) patients in GI and GII respectively. The mean IIQ-7 was reduced from 63.38 AE 8.81 to 31.99 AE 9.26 (p<0.001) for GII vs. 64.33 AE 8.57 to 51.86 AE 17.26 (0.002) for GI. Before treatment, 11 (73.3%) and 4 (26.7%) patients in each group had moderate and poor quality of life respectively. After treatment, 6 (40%) and 14 (93.3%) had good quality of life, 7 (46.7%) and 1 (6.7%) had moderate quality of life in GI and GII respectively. Two (13.3%) in GI had poor quality of life. The mean frequency for GII after treatment was 8.60 AE 0.83 instead of 12.87 AE 1.85 (p<0.001) before treatment, while it was reduced from 13.13 AE 1.64 to 10.60 AE 2.32 (p¼0.003) in GI. The cystometric capacity improved from 263.40 AE 50.45 ml to 377.80 AE 112.92 ml (p¼0.001) for GII Vs. 250.13 AE 56.24 ml to 296.40 AE 99.0 ml (p¼0.026) for GI.
CONCLUSIONS: TPTNS combined with low dose trospium chloride proved to be more effective than TPTNS alone in the treatment of OAB in females.
Source of Funding: none
PD54-11 ELECTRICAL STIMULATION OF AFFERENT NERVES IN THE FOOT WITH TRANSCUTANEOUS ADHESIVE PAD ELECTRODES IN WOMEN WITH REFRACTORY OVERACTIVE BLADDER: DEFINING IDEAL STIMULATION DURATION
Christopher J Chermansky*, Bing Shen, Janet Okonski, William C de Groat, Changfeng Tai, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: A non-invasive and convenient overactive bladder (OAB) treatment with no major adverse events would be ideal. We previously showed that stimulation of afferent nerves in the foot for 3 hours daily with transcutaneous adhesive pad electrodes (FootStim) decreased urgency urinary incontinence (UUI) and urgency frequency in women with refractory OAB. Yet, the ideal stimulation duration remains unknown. In this study, we
